1. Nuvaxovid, a recombinant protein-based COVID-19 vaccine, is approved for adults aged 65+ and individuals aged 12-64 with underlying conditions.
2. Novavax will receive a milestone payment from Sanofi.
3. Postmarketing commitments include a Phase 4 trial in adults aged 50-64 without high-risk conditions.
4.  Adverse events reported include injection site tenderness, headache, fatigue, myalgia, fever, and nausea.
5. The vaccine is contraindicated in individuals with a history of severe allergic reactions.
6. Reduced vaccine efficacy is expected in immunocompromised patients.
7. Nuvaxovid has full market approvals in various countries.

Source: Novavax Inc.